

Electronic supplementary material

ESM Table 1 ANCOVA of primary endpoint: change of HbA_{1c} (%) – per protocol analysis set

Comparison of change from baseline in HbA _{1c} after 26 weeks of treatment						
Treatment/comparison	Estimates			Testing		
	<i>n</i>	LS mean	SE			
Liraglutide 1.8 mg	195	-1.35	0.09			
Main	205	-1.10	0.09			
Secondary	90	-0.35	0.11			
Estimated treatment differences	LS mean	95% CI		Hypothesis	<i>p</i> value	Conclusion
Liraglutide 1.8 mg: secondary	-1.00	-1.19, -0.80		Superior	<0.0001*	Yes
Liraglutide 1.8 mg: main	-0.25	-0.40, -0.09		Non-inferior	<0.0001*	Yes
Liraglutide 1.8 mg: main	-0.25	-0.40, -0.09		Superior	0.0008*	Yes
Liraglutide 1.8 mg: secondary	-0.75	-0.94, -0.55		Superior	<0.0001*	Yes

*Statistical significance on a 2.5% level

LS, Least square